Kenvue Inc. (KVUE)

Republicans and Democrats are divided along party lines as to whether they believe the U.S. government's claim that women who take Tylenol during pregnancy are raising the risk of autism in their unborn children, a new poll from KFF found.

It's fun to follow stocks that soared recently, and it can be sobering to see which ones have plunged -- especially if you're a shareholder. So here's a look at the worst-performing stocks in the S&P 500 index of 500 of America's biggest companies -- in September.

Investors are wondering if the recent weakness in Kenvue (KVUE 3.28%) stock is a buying opportunity for long-term buyers.

Kenvue (KVUE 2.61%) is under attack by the government, which accuses the company of selling unsafe products to pregnant women.

In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.

Cullen Capital Management, LLC disclosed the sale of 6,565,339 shares of Kenvue (KVUE -0.77%) for the period ended Q2 2025. The transaction was valued at an estimated $149.46 million.

Kenvue faces near-term headwinds from Tylenol-autism allegations, macro uncertainty, and segment underperformance, but offers long-term income potential. Recent leadership changes and a focus on core brands and technology could drive future improvements, though execution risk remains amid economic challenges. KVUE's forward dividend yield near 5% and a solid balance sheet make it attractive for income-focused investors despite limited near-term upside.

A pair of United States lawmakers sold shares in Tylenol's parent company, Kenvue (NYSE: KVUE), just days before President Donald Trump made controversial remarks linking the painkiller to autism.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.

U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offered further healthcare advice not backed by science.

The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net gains of 21.59% to 66.98% by September 2026 for these high-yield 'dog' stocks, with average risk 31% below the market. Five lowest-priced Hi-Yield Aristocrats—AMCR, FLO, PRGO, BEN, RHI—are expected to outperform the higher-priced group, reflecting the classic 'Dogs of the Dow' strategy.

Tylenol may be only the beginning.

Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consider President Donald Trump's new advice that pregnant women avoid the pain killer as it decides whether to revive their lawsuits.

The heads of key health agencies advocated for putting the emphasis on leucovorin, but Kennedy became convinced that he had a moral duty to get the word out about the risk of acetaminophen.

Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity. The market reaction appears to be an overreaction, as Tylenol accounts for roughly $1 billion in sales and a fraction of Kenvue's total revenue. The current valuation implies an unrealistic 40%+ decline in Tylenol sales, which seems excessive given the actual business impact.